Condition
Zollinger-Ellison Syndrome
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
100%
3 of 3 completed with results
Key Signals
3 with results75% success
Data Visualizations
Phase Distribution
4Total
P 2 (1)
P 3 (2)
P 4 (1)
Trial Status
Completed3
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02454075Phase 2TerminatedPrimary
YF476 and Type II Gastric Carcinoids
NCT02153398Phase 3Completed
A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
NCT00204373Phase 4CompletedPrimary
Treatment of Zollinger-Ellison Syndrome With Prevacid
NCT00079833Phase 3CompletedPrimary
Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome
Showing all 4 trials